Passage Bio rises on FDA nod for gene therapy trial
08/06/2022 13:32
** Shares in gene therapy co Passage Bio PASG.O rise 2.7%
to $2.66 premarket
** Co says U.S. FDA has cleared its application to start an
early-stage study of its experimental therapy, PBML04, in
Metachromatic Leukodystrophy patients (https://refini.tv/3QaWl0L)
** Metachromatic leukodystrophy is a genetic disorder that
causes fatty substances to build up in cells
** Seven out of nine analysts covering the stock rate it
'buy' or higher, two rate 'hold'; their median PT is $10.00 -
Refinitiv data
* Up to Tuesday's close, PASG had lost 59.2% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))